Claims for Patent: 5,552,520

Summary for Patent: 5,552,520

Title:	Therapeutic peptide derivatives
Abstract:	Peptide derivatives containing one or more substituents separately linked by an amide, amino or sulfonamide bond to an amino group on either the N-terminal end or side chain of a biologically active peptide moiety. The peptide derivatives have relatively enhanced biological activity when compared to the corresponding peptide alone.
Inventor(s):	Kim; Sun H. (Chestnut Hill, MA), Keyes; Susan R. (Boston, MA), Moreau; Sylviane (Upton, MA), Dong; Zheng X. (Framingham, MA), Taylor; John (Upton, MA)
Assignee:	Biomeasure, Inc. (Milford, MA)
Application Number:	08/287,957
Patent Claims:	1. A peptide derivative consisting of: a biologically active peptide moiety having a free amino group, and at least one substituent attached to said peptide moiety, wherein said substituent is selected from the group consisting of Compounds I, II, and III, wherein Compound I is: ##STR20## wherein: R.sub.0 is O, S, or NR.sub.5, wherein R.sub.5 is H or (C.sub.1 -C.sub.6) alkyl; each R.sub.1 and R.sub.2, independently, is H, (CH.sub.2).sub.m OR.sub.6, or CH(OR.sub.7)CH.sub.2 OR.sub.8, wherein R.sub.6 is H or (C.sub.2 -C.sub.7) acyl, and each R.sub.7 and R.sub.8, independently, is H, (C.sub.2 -C.sub.7) acyl, or C(R.sub.9)(R.sub.10), wherein each R.sub.9 and R.sub.10, independently, is H or C.sub.1 -C.sub.6 alkyl; or R.sub.1 and R.sub.2 in combination are .dbd.CHCH.sub.2 OR.sub.11, R.sub.11 is H or (C.sub.2 -C.sub.7) acyl, and m is an integer between 1 and 5, inclusive; and one of R.sub.3 and R.sub.4 is (CH.sub.2).sub.n R.sub.12 or (CH.sub.2).sub.n CH(OH)R.sub.12, wherein R.sub.12 is CO, CH.sub.2 or SO.sub.2, and n is an integer between 1 and 5, inclusive; and the other of R.sub.3 and R.sub.4 is H, (C.sub.1 -C.sub.6) hydroxyalkyl, or (C.sub.2 -C.sub.7) acyl; and Compound II is: ##STR21## wherein: each R.sub.13, R.sub.14, and R.sub.15, independently, is H or (C.sub.2 -C.sub.24) acyl; R.sub.16 is NH or absent; R.sub.17 is CO, O, or absent; R.sub.18 is CO, CH.sub.2, SO.sub.2, or absent; m is an integer between 1 and 5, inclusive; n is an integer between 1 and 5, inclusive; and Compound III is: ##STR22## wherein: R.sub.19 is H, NH.sub.2, an aromatic functional group, OH, (C.sub.1 -C.sub.6) hydroxyalkyl, H(R.sub.27)(R.sub.28), SO.sub.3 H, or absent; wherein each R.sub.27 and R.sub.28, independently, is H or (C.sub.1 -C.sub.6) alkyl; R.sub.20 is O or absent; R.sub.21 is (C.sub.1 -C.sub.6) alkyl or absent; R.sub.22 is N, O, C, or CH; R.sub.23 is (C.sub.1 -C.sub.6) alkyl or absent; R.sub.24 is N, CH, or C; R.sub.25 is NH, O, or absent; R.sub.26 is SO.sub.2, CO, or CH.sub.2 ; m is an integer between 0 and 5, inclusive; n is an integer between 0 and 5, inclusive; p is an integer between 0 and 5, inclusive; and q is an integer between 0 and 5, inclusive; wherein said peptide moiety is attached to said substituent at R.sub.12, R.sub.18, or R.sub.26 by a CO--N, CH.sub.2 --N, or SO.sub.2 --N bond between said substituent and said free amino group. 2. The peptide derivative of claim 1, wherein said substituent is Compound I. 3. The peptide derivative of claim 1, wherein said substituent is Compound II. 4. The peptide derivative of claim 1, wherein said substituent is Compound III. 5. The peptide derivative of claim 2, wherein R.sub.0 is O, R.sub.1 is CH(OH)CH.sub.2 OH, R.sub.2 is H, and one of R.sub.3 and R.sub.4 is (CH.sub.2).sub.n R.sub.12 and the other of R.sub.3 and R.sub.4 is H or (C.sub.1 -C.sub.6) hydroxyalkyl. 6. The peptide derivative of claim 3, wherein R.sub.13, R.sub.14, and R.sub.15 are H, R.sub.16 is NH, R.sub.17 is CO or absent, and m is O. 7. The peptide derivative of claim 3, wherein R.sub.13, R.sub.14, and R.sub.15 are H, R.sub.16 is absent, R.sub.17 is absent, and m is O. 8. The peptide derivative of claim 4, wherein R.sub.23 is (C.sub.1 -C.sub.6) alkyl, R.sub.22 is N, C, or CH, R.sub.24 is C, and each of m and n is an integer between 2 and 5, inclusive. 9. The peptide derivative of claim 4, wherein R.sub.23 is absent, R.sub.24 is N or CH, R.sub.22 is N, O, or C, and each of m and n is an integer between 2 and 5, inclusive. 10. The peptide derivative of claim 9, wherein R.sub.24 is N, R.sub.22 is O, and each of R.sub.19, R.sub.20, and R.sub.21 is absent. 11. The peptide derivative of claim 9, wherein each of R.sub.22 and R.sub.24 is N. 12. The peptide derivative of claim 11, wherein each of R.sub.20 and R.sub.25 is absent. 13. The peptide derivative of claim 12, wherein R.sub.19 is OH, R.sub.21 is (C.sub.1 -C.sub.6) alkyl, and p is 0. 14. The peptide derivative of claim 5, wherein said peptide moiety is selected from the group consisting of: somatostatin, bombesin, calcitonin, calcitonin gene related peptide, amylin, parathyroid hormone, gastrin releasing peptide, melanocyte stimulating hormone, adrenocorticotrophic hormone, parathyroid related peptide, luteinizing hormone-releasing hormone, growth hormone releasing factor, growth hormone releasing peptide, cholecystokinin, glucagon, bradykinin, glucagon-like peptide, gastrin enkephalin, neuromedins, endothelin, substance P, neuropeptide Y, peptide YY, vasoactive intestinal peptide, guanylin, pituitary adenylate cyclase activating polypeptide, beta-cell tropin, adrenomedullin, and a derivative, a fragment, or an analog thereof. 15. The peptide derivative of claim 14, wherein said peptide moiety is somatostatin or a derivative, a fragment, or an analog thereof. 16. The peptide derivative of claim 6, wherein said peptide moiety is selected from the group consisting of: somatostatin, bombesin, calcitonin, calcitonin gene related peptide, amylin, parathyroid hormone, gastrin releasing peptide, melanocyte stimulating hormone, adrenocorticotrophic hormone, parathyroid related peptide, luteinizing hormone-releasing hormone, growth hormone releasing factor, growth hormone releasing peptide, cholecystokinin, glucagon, bradykinin, glucagon-like peptide, gastrin enkephalin, neuromedins, endothelin, substance P, neuropeptide Y, peptide YY, vasoactive intestinal peptide, guanylin, pituitary adenylate cyclase activating polypeptide, beta-cell tropin, adrenomedullin, and a derivative, a fragment, and an analog thereof. 17. The peptide derivative of claim 16, wherein said peptide moiety is somatostatin or a derivative, a fragment, or an analog thereof. 18. The peptide derivative of claim 7, wherein said peptide moiety is selected from the group consisting of: somatostatin, bombesin, calcitonin, calcitonin gene related peptide, amylin, parathyroid hormone, gastrin releasing peptide, melanocyte stimulating hormone, adrenocorticotrophic hormone, parathyroid related peptide, luteinizing hormone-releasing hormone, growth hormone releasing factor, growth hormone releasing peptide, cholecystokinin, glucagon, Bradykinin, glucagon-like peptide, gastrin enkephalin, neuromedins, endothelin, substance P, neuropeptide Y, peptide YY, vasoactive intestinal peptide, guanylin, pituitary adenylate cyclase activating polypeptide, beta-cell tropin, adrenomedullin, and a derivative, a fragment, or an analog thereof. 19. The peptide derivative of claim 18, wherein said peptide moiety is somatostatin or a derivative, a fragment, or an analog thereof. 20. The peptide derivative of claim 13, wherein said peptide moiety is selected from the group consisting of: somatostatin, bombesin, calcitonin, calcitonin gene related peptide, amylin, parathyroid hormone, gastrin releasing peptide, melanocyte stimulating hormone, adrenocorticotrophic hormone, parathyroid related peptide, luteinizing hormone-releasing hormone, growth hormone releasing factor, growth hormone releasing peptide, cholecystokinin, glucagon, Bradykinin, glucagon-like peptide, gastrin enkephalin, neuromedins, endothelin, substance P, neuropeptide Y, peptide YY, vasoactive intestinal peptide, guanylin, pituitary adenylate cyclase activating polypeptide, beta-cell tropin, adrenomedullin, and a derivative, a fragment, or an analog thereof. 21. The peptide derivative of claim 20, wherein said peptide moiety is somatostatin or a derivative, a fragment, or an analog thereof. 22. The peptide derivative of claim 21, wherein said somatostatin analog is: H-D-Phe-c[Cys-Try-D-Trp-Lys-Abu-Cys]-Thr-NH.sub.2, H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH.sub.2, or H-D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH.sub.2. 23. The peptide derivative of claim 14, wherein said substituent is one of: ##STR23## 24. The peptide derivative of claim 1, wherein said peptide moiety is selected from the group consisting of: somatostatin, bombesin, calcitonin, calcitonin gene related peptide (CGRP), amylin, parathyroid hormone (PTH), gastrin releasing peptide (GRP), melanocyte stimulating hormone (MSH), adrenocorticotrophic hormone (ACTH), parathyroid related peptide (PTHrP), luteinizing hormone-releasing hormone (LHRH), growth hormone releasing factor (GHRF), growth hormone releasing peptide (GHRP), cholecystokinin (CCK), glucagon, Bradykinin, glucagon-like peptide (GLP), gastrin, enkephalin, neuromedins, endothelin, substance P, neuropeptide Y (NPY), peptide YY (PYY), vasoactive intestinal peptide (VIP), guanylin, pituitary adenylate cyclase activating polypeptide (PACAP), beta-cell tropin, adrenomedulin, and derivatives, fragments, and analogs thereof. 25. The peptide derivative of claim 24, wherein said peptide moiety is somatostatin or a derivative, fragment, or analog thereof. 26. The peptide derivative of claim 25, wherein said somatostatin analog is one of: H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH.sub.2, (SEQ ID NO. 112); H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH.sub.2, (SEQ ID NO. 113); and H-D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH.sub.2 (SEQ ID NO. 112) . 27. The peptide derivative of claim 24, wherein said peptide moiety is bombesin or a derivative, fragment or analog thereof. 28. The peptide derivative of claim 1, wherein said peptide derivative is one of: ##STR24##

Details for Patent 5,552,520

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2013-09-03